A Grupe

Plain English
Researchers spent nine years cataloging mushrooms and other large fungi at a Florida nature preserve, identifying over 546 species and estimating the actual total is probably between 900 and 1,200 species—meaning there are more fungal species at this one site than there are vertebrate animals or plants. They used DNA testing to precisely identify each specimen and created a reference collection for future research. This matters because fungi are essential to forest ecosystems (they help trees absorb nutrients and break down dead material), yet scientists know far less about fungal diversity than they do about plants and animals, making this comprehensive catalog a crucial foundation for understanding and protecting Florida's ecosystems.

Plain English
Researchers identified two new edible truffle species growing wild in eastern North America by using trained dogs to sniff them out, then confirmed the discoveries through genetic testing and chemical analysis of their aromas. These truffles have culinary value and distinctive smells caused by compounds like dimethyl sulfide, making them potentially valuable for harvesting and selling. The findings show that truffle-hunting dogs are an effective tool for discovering unknown fungi in North America, where many undescribed edible species likely still exist.

Plain English
Researchers developed a faster, more efficient way to read the complete genetic code of the COVID-19 virus directly from patient samples, allowing a single lab to analyze nearly 2,700 samples at once instead of just a few. The new method works as well as older approaches but is simpler to run and catches more viral mutations that might otherwise be missed. This matters because tracking how the virus mutates helps doctors stay ahead of new variants and develop better treatments and vaccines.

Plain English
Researchers spent five years testing whether they could grow pecan truffles (expensive, flavorful fungi) on pecan tree seedlings by treating soil with chemicals to kill competing fungi and then adding truffle spores. They found that treating the soil and adding truffles together worked best, and that seedlings should be transplanted after 2-3 years for the strongest truffle growth. The results show that pecan truffles can be grown using methods that fit into existing pecan nursery operations, opening the door to commercially farming these valuable fungi alongside pecan trees.

Plain English
Researchers developed and tested a genetic screening tool that checks 48 genes for mutations in blood cancers like acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms—including genes that are notoriously hard to analyze with standard methods. The test was nearly perfect, correctly identifying mutations 99.6% of the time with zero false positives, and when applied to over 2,000 patients, it found disease-causing mutations in about half of them (77% of acute leukemia patients, 48% of myelodysplastic patients, and 45% of myeloproliferative patients). This matters because identifying these specific mutations helps doctors diagnose blood cancers accurately and choose the right treatment for each patient.

Plain English
Researchers at ASCO (a major cancer medicine organization) recruited 49 cancer doctors and healthcare workers to track how they learn and what educational resources they actually use over nine months, asking them to report their learning needs and feedback monthly. They found that this approach successfully captured real information about how cancer professionals prefer to learn and which educational tools are most helpful to them. This method can now be used to design better training programs for cancer care workers based on what they actually need rather than guessing.

Plain English
Researchers tracked 32 cancer doctors and nurses for nine months to understand how they figure out what they need to learn and what type of learning works best for them. They found that doctors and nurses discover learning gaps differently depending on their job title and where they work—for example, advanced practice providers often learn about gaps from colleagues, while patient cases drive learning needs for almost everyone. When choosing how to learn, providers prioritize convenience and quality content, and their preferred learning methods vary based on their workplace setting and location.

Plain English
Researchers created and tested a genetic test that checks 34 genes known to increase cancer risk in families; the test successfully identified cancer-causing genetic mutations with near-perfect accuracy in over 600 patient samples. When they used this test on their first 500 patients, they found dangerous mutations in about 10% of them, mostly in well-known cancer genes like BRCA1 and BRCA2, but also in less famous genes that doctors hadn't been routinely checking before. This test allows doctors to identify people at high risk for inherited cancers so they can monitor these patients more closely and potentially prevent cancer through early screening or preventive treatment.

Plain English
Researchers at ASCO (a major cancer doctors' organization) surveyed 49 cancer care professionals over nine months to find out how they prefer to learn and what educational resources they actually use. They discovered that doctors' ages and where they work significantly influence what type of learning materials and teaching methods work best for them. These findings suggest that ASCO and other medical organizations can create better educational programs by customizing them to match different groups of doctors' specific needs and preferences.

Plain English
Researchers identified two previously unknown species of truffles living in pecan orchard soil that form mutually beneficial partnerships with pecan tree roots. These truffles—named *Tuber brennemanii* and *Tuber floridanum*—are actually among the most abundant fungi in pecan orchards across multiple regions, thriving especially in disturbed or nutrient-rich soils. This matters because understanding which fungi naturally associate with pecan trees could help farmers improve orchard health and productivity, and it shows how fungal species can spread internationally on plant material, which has implications for agriculture and ecosystem management.

Plain English
Scientists discovered a new species of truffle growing in central Mexico and identified it as distinct from other similar truffles through its physical characteristics (like spore size and color) and its unique DNA sequence. This new truffle belongs to a specific family group called the Maculatum clade and grows in association with a particular tree species found only in that region. The discovery adds to our understanding of truffle biodiversity in Mexico and helps scientists better classify these underground fungi.

Plain English
Researchers created OncoKB, a searchable database that catalogs what happens when specific genetic mutations appear in cancer tumors and which drugs might work against them, drawing on FDA approvals, clinical guidelines, and scientific research. They tested this database on nearly 6,000 tumor samples across 19 cancer types and found that 41% contained mutations that could potentially be treated with existing drugs, though only 7.5% had strong evidence that a standard treatment would actually work. Doctors and researchers can now use OncoKB online to quickly look up a patient's tumor mutations and get evidence-based recommendations about which treatments might help, rather than having to search through thousands of scientific papers themselves.

Plain English
Researchers found four previously unknown species of tooth fungi (called Sarcodon) in the Colombian Amazon rainforest, bringing the total known species in South America to ten. These fungi live in partnership with specific rainforest trees, helping them absorb nutrients from the soil while getting food from the trees in return. The discovery is documented with detailed descriptions, photos, genetic testing, and an identification guide so scientists can recognize these species in the future.

Plain English
Researchers tested a genetic screening tool on 121 cancer samples (melanoma, lung, colorectal, and breast cancer) to see if it could find more cancer-causing mutations than standard testing methods. The new test found additional mutations in 74% of samples that standard testing had missed, including 16 samples with mutations in genes known to guide treatment decisions, with no false results. The test successfully identified mutations across most of the 34 genes it screens for, with TP53 being the most commonly mutated gene, and discovered that most cancer samples carried mutations in at least one gene that could affect treatment choices. This matters because finding more mutations gives doctors better information to choose the most effective treatments for each patient's specific cancer.

Plain English
Researchers discovered four completely new species of fungi in tropical forests across Guyana, Puerto Rico, and Belize—places where this type of fungus had rarely or never been found before. These fungi form underground partnerships with tree roots to help the trees absorb nutrients from the soil, and scientists confirmed they were new species by examining their physical appearance and analyzing their DNA. This discovery matters because almost all known species of this fungus live in cold forests in the northern hemisphere with conifer trees, so finding four new species thriving in warm tropical forests with completely different trees suggests this fungus is far more widespread and diverse than scientists realized.

Plain English
Researchers studied 275 European children with unexplained short stature who had normal growth hormone levels to understand why they weren't growing normally. They measured growth-related proteins in the children's blood and searched for genetic mutations that might explain their short stature. They found that about half of these children had low levels of a growth protein called IGF-I, and they identified several genes—including one called IGF1—that were more common in short children than in normal-height children. Importantly, genes involved in controlling how cells process growth signals, not just growth hormone genes, appeared to play a role in short stature. This matters because it shows that unexplained short stature has multiple genetic causes beyond just the growth hormone system, which could help doctors eventually identify why individual children aren't growing normally and potentially develop better treatments.

Plain English
Researchers tested 97 genetic variants in people aging normally to see which ones affected how quickly Alzheimer's disease developed and how much brain volume people lost. They found that one specific genetic variant in the FAS gene made Alzheimer's progress faster and was linked to smaller brains and larger fluid-filled spaces in the brain. This matters because FAS controls a process that kills off brain cells, so this finding suggests that differences in how this gene works may determine how quickly someone develops Alzheimer's disease.

Plain English
Researchers studied a specific genetic variation in a brain protein called BDNF to see if it increases Alzheimer's disease risk, combining their own data from 657 Japanese patients with information from 16 other research centers worldwide. They discovered that women who carry a particular version of this gene (called Met66) are 14% more likely to develop Alzheimer's, but this genetic risk doesn't apply to men. This matters because it shows that Alzheimer's risk genes don't affect men and women equally—a finding that could eventually lead to more personalized prevention strategies based on sex and genetics.

Plain English
Researchers tested whether a specific set of 23 genetic markers could predict Parkinson's disease risk, as a previous study claimed. When they tested these markers in their own patient groups, they found almost no connection to the disease—a dramatic difference from the original study's claims. The researchers then showed how the original study likely made a statistical error: when they built similar genetic prediction models using completely random genes, they got equally impressive-looking results, proving the original findings were probably just flukes rather than real biology. This means the genetic pathway previously identified doesn't actually help predict who will get Parkinson's disease, and doctors shouldn't rely on these genetic markers.

Plain English
Researchers found that a small genetic variation in a gene called NEDD9 increases the risk of developing Alzheimer's disease and Parkinson's disease later in life. They discovered this by examining genetic data from thousands of patients and found that people carrying this variation were about 30-40% more likely to develop these diseases. The finding matters because it identifies a new biological target that could help scientists understand why these diseases develop and potentially lead to new treatments or preventive strategies.

Plain English
Researchers tested whether specific genetic variations in a gene called SORL1 increase the risk of Alzheimer's disease in older adults, based on a previous study's findings. They examined about 2,000 people with and without Alzheimer's and found only weak evidence that one genetic variant might matter—and that weak signal disappeared when they properly accounted for testing multiple genetic variants. More research is needed to determine whether SORL1 genetic variations actually affect Alzheimer's risk.

Plain English
Researchers know that a gene called APOE e4 increases Alzheimer's risk, but they've struggled to find other genetic factors that reliably predict the disease because most other genes have only tiny effects on risk. Scientists believe many weak genetic factors work together with APOE e4 to cause late-onset Alzheimer's, so they need to combine data from large populations to find these hidden genetic clues. Once they identify these genes, doctors could create better tests to predict who will get Alzheimer's, develop new drugs to prevent it, and figure out which treatments work best for each person.

Plain English
Researchers measured levels of a protein called apoE in the spinal fluid of 168 people to see if genetic variations in a gene called ABCA1 affect how much apoE is present in the brain—since apoE is thought to influence Alzheimer's disease risk by controlling buildup of harmful proteins in the brain. They found that apoE levels stayed consistent in the same person over time but varied widely between different people, and these levels increased slightly with age, but genetic variations in ABCA1 made no difference to apoE levels. The findings matter because they suggest that if ABCA1 genetic variations do play a role in Alzheimer's disease, it's not by controlling apoE levels in the brain, so researchers need to look for other ways this gene might increase disease risk.

Plain English
Researchers scanned the genes of nearly 1,900 Alzheimer's patients and 2,000 healthy people to find genetic variations that increase the risk of developing the disease later in life. They discovered multiple genetic markers linked to Alzheimer's, including some near the well-known APOE gene and several in other genes that hadn't been previously connected to the disease. These findings could eventually help doctors identify who is most likely to develop Alzheimer's and potentially lead to new treatments by revealing biological pathways involved in the disease.

Plain English
Researchers studied whether specific genetic variations in two genes called USP24 and USP40 increase the risk of developing Parkinson's disease later in life, testing DNA from over 400 people with and without the disease. They found that certain genetic variants in both genes were significantly more common in people with Parkinson's disease than in healthy people, even when they tested a larger group to confirm their results. This discovery matters because it points to a specific biological mechanism (the ubiquitination pathway) that may actually cause Parkinson's disease, which could eventually lead to new treatments.

Plain English
Researchers found that two genetic variations in a gene called DAPK1 are associated with Alzheimer's disease risk—people who carry certain versions of these genetic variants are less likely to develop the disease. They confirmed this finding by testing over 4,000 people across multiple studies, and they discovered that these same genetic variations affect how much DAPK1 protein the body produces. Why it matters: This identifies a new genetic target that could help scientists understand what goes wrong in Alzheimer's disease and potentially develop new treatments.

Plain English
Researchers scanned chromosome 10 using genetic markers in over 1,400 people to find which genes increase the risk of Alzheimer's disease in older adults. They discovered that a specific genetic variant near a gene called RPS3A showed a strong and consistent link to Alzheimer's disease across multiple groups of patients. This finding identifies a new genetic risk factor for Alzheimer's disease and points to a specific location on chromosome 10 where scientists should focus their efforts to understand how the disease develops.

Plain English
Researchers tested whether variations in a gene called ubiquilin 1 increase the risk of Alzheimer's disease in older adults, based on earlier studies suggesting a link. They examined this gene in over 3,000 people—half with Alzheimer's and half without—and found no connection between any of the genetic variations they studied and Alzheimer's risk.

Plain English
Researchers tested whether genetic variations in a specific gene called IDE increase the risk of developing Alzheimer's disease in older adults, since this gene is involved in clearing harmful protein buildup in the brain. They examined genetic data from over 2,400 people and found that while one genetic variant showed a weak link to Alzheimer's in two groups, this finding didn't hold up in the other two groups they tested, and no other variants showed any consistent connection. The conclusion is that common genetic variations in the IDE gene are not a major cause of late-onset Alzheimer's disease.

Plain English
Researchers tested whether variations in a gene called APBB2 increase the risk of late-onset Alzheimer's disease (the most common form, occurring after age 65) by studying about 2,000 people with and without the disease. They found that people with certain genetic variants in APBB2 had a significantly higher chance of developing Alzheimer's, especially those who developed the disease before age 75. This matters because it identifies a new genetic risk factor for Alzheimer's disease, which could eventually help doctors identify who's at highest risk and possibly lead to new treatments targeting this gene.

Plain English
Researchers studied over 2,000 people to find genetic differences that increase the risk of Alzheimer's disease in older adults, and they discovered that variations in three related genes called GAPD are associated with the disease. These GAPD genes appear to work together to influence Alzheimer's risk, and the strength of that influence varies depending on a person's genetic background—meaning different combinations of these gene variants matter more or less in different populations. This matters because it identifies new biological targets that could explain how Alzheimer's develops and potentially lead to new treatments, since these genes are known to be involved in the death of brain cells, a key feature of the disease.

Plain English
Researchers tested whether specific genetic variations in the ABCA1 gene increase the risk of Alzheimer's disease in 796 people (419 with Alzheimer's and 377 without), but found no connection between these genes and the disease. A previous study had claimed this gene variant was linked to Alzheimer's, but this larger study couldn't confirm that finding, meaning the original result was likely wrong. This matters because it shows scientists need to be careful about which genetic discoveries are real before investing time and money into developing treatments based on them.

Plain English
Researchers investigated whether a gene called CTNNA3 on chromosome 10 causes Alzheimer's disease, since this region of DNA has been linked to the disease and the gene produces a protein active in the brain that affects cellular pathways involved in neurodegeneration. After testing over 30 genetic variations in this gene across more than 1,200 people with and without Alzheimer's, they found no connection between any of these variations and the disease. This means that while CTNNA3 is an attractive suspect based on its location and function, it is not responsible for the increased Alzheimer's risk associated with chromosome 10, so researchers need to look elsewhere for the actual culprit gene.

Plain English
Researchers found that people with a specific genetic variation in the TCF7 gene are more likely to develop type 1 diabetes, particularly when they don't carry certain other high-risk genes. Type 1 diabetes occurs when the immune system mistakenly attacks the insulin-producing cells in the pancreas, and TCF7 is a gene that controls immune system function. This discovery means that TCF7 is one of the genetic factors that influence whether someone will develop this disease, and it may also affect when the disease appears in a person's life.

Plain English
Researchers created a computer program that quickly identifies which parts of mouse DNA control diseases, using a database of genetic variations across different mouse breeds. Instead of spending months doing lab experiments to find disease-causing genes, scientists can now enter information about a sick mouse's symptoms and the program instantly predicts which chromosome regions are responsible. This speeds up the discovery of disease genes in mice, which helps scientists understand how the same diseases work in humans.

Plain English
Researchers found that mice lacking a properly functioning C5 gene (which produces a protein involved in immune response) are more susceptible to developing asthma-like airway problems when exposed to allergens. The C5 protein normally helps immune cells produce a substance called IL-12 that protects against allergic asthma, so without it, this protective mechanism fails. This discovery matters because it identifies a specific genetic target that could potentially be manipulated to prevent or treat allergic asthma in humans.

Plain English
Researchers used different strains of mice to find which genes control asthma-like symptoms, specifically the tendency for airways to overreact to allergens. They discovered that different mouse strains responded differently to allergen exposure, and they identified two specific locations on mouse chromosome 2 that contain genes controlling airway overreactivity, plus another possible location on chromosome 7. This matters because it reveals which genes drive asthma symptoms in mice, which could help scientists understand what goes wrong in human asthma and potentially lead to new treatments.

Plain English
Researchers studied why T cells from different mouse strains respond differently to a immune signal called IL-12—some mice's T cells keep their receptors for IL-12 and stay responsive to it, while other mice's T cells lose those receptors and stop responding. They found a specific gene region on mouse chromosome 11, called Tpm1, that controls whether T cells maintain these receptors. The effect happens inside the T cell itself, not from signals coming from outside the cell, which means the gene likely directly controls receptor production rather than working through other immune molecules nearby.

Plain English
Researchers studied how pancreatic cells respond to high blood sugar in mice with a defective glucose-sensing gene (glucokinase). They found that when these defective cells were exposed to high sugar levels for 2-4 days, they compensated by producing more of the broken gene's protein, which actually improved their ability to sense and respond to sugar by releasing insulin—though not perfectly. In contrast, normal cells exposed to the same high sugar conditions got worse at their job, showing that prolonged high blood sugar damages healthy pancreatic cells but paradoxically helps defective ones adapt. This explains why people with glucokinase gene mutations develop mild, stable high blood sugar rather than progressively worse diabetes.

Plain English
Researchers studied how a protein called GATA-3 controls the production of IL-4, a chemical messenger that immune cells make during allergic reactions and infections. They found that GATA-3 alone is not enough to fully turn on IL-4 production—the gene needs help from other DNA regions (called enhancers) located far from the main promoter to reach normal levels. This matters because understanding how IL-4 gets switched on could lead to new treatments for allergies, asthma, and autoimmune diseases by either boosting or blocking this immune response.

Plain English
Researchers created genetically modified mice to understand how the pancreas senses blood sugar and releases insulin in response. They found that an enzyme called glucokinase in pancreatic beta cells is absolutely essential for this process—without it, mice die shortly after birth with dangerously high blood sugar, and even mice with only half the normal amount of this enzyme have elevated blood sugar and produce less insulin. This discovery matters because it proves that glucokinase is the body's glucose sensor and reveals why defects in this gene cause a form of diabetes in humans.

Plain English
Researchers studied a protein called PC-1 that is abnormally high in people with insulin resistance, and found that it blocks insulin from working properly in cells. They discovered that PC-1 stops insulin from working through a completely different mechanism than scientists previously thought—it's not about breaking down energy molecules (ATP) or creating a chemical messenger (adenosine), even though PC-1 normally does those things. This finding matters because it reveals the true way PC-1 causes insulin resistance, which could lead to better treatments for diabetes.

Plain English
Researchers studied why people with type 2 diabetes can't use insulin properly, even though their insulin receptors appear genetically normal. They discovered that a protein called PC-1 blocks insulin from working correctly in cells, and this protein is overactive in most type 2 diabetes patients they tested. This matters because it identifies a specific culprit for insulin resistance—rather than a defective insulin receptor itself, the problem is a natural brake on the system that's stuck in the "on" position, which could eventually lead to new treatments that turn off this brake.

Plain English
Researchers identified a human gene called HK1 that produces a protein controlling electrical signals in heart cells, and they pinpointed its exact location on chromosome 11. This gene sits near another gene (FSHB) and in a region of the chromosome known to cause birth defects when deleted. Finding where this gene lives matters because it could help explain why certain genetic deletions cause heart problems alongside other developmental disorders.

Plain English
Researchers discovered a new potassium channel protein in the human brain (called HBK2) that controls how electrical signals move in and out of brain cells. This protein has an unusual structure compared to similar channels found in other animals, particularly a longer connector region that may be modified differently than other channel proteins. When the team tested this channel in lab cells, it behaved differently from other known potassium channels, suggesting it may have unique roles in brain function.